Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Early Response Parameters during Etoposide-Based Hemophagocytic Lymphohistiocytosis Treatment in Children Predict Early Mortality

Joanne Yacobovich, Bethany Verkamp, Brenton J Francisco, Joana Marie Mack, Tucker Blackledge, Dafna Brik Simon, Adi Zoref-Lorenz, Michael B Jordan

Blood (2022) 140 (Supplement 1): 2612–2613.

https://doi.org/10.1182/blood-2022-167637

Published: 2022

Journal Articles

Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study

Carl E. Allen, Shanmuganathan Chandrakasan, Michael B Jordan, Jennifer W Leiding, Abiola Oladapo, Priti Pednekar, Kelly J. Walkovich, John Yee

Blood (2022) 140 (Supplement 1): 2595–2596.

https://doi.org/10.1182/blood-2022-166649

Published: 2022

Journal Articles

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): The into-HLH Registry

Adi Zoref-Lorenz, David C. Fajgenbaum, Sheila K. Pierson, Abiola Oladapo, John Yee, Nitya Gulati, Carl E. Allen, Michael B. Jordan

Blood (2022) 140 (Supplement 1): 11170–11171.

https://doi.org/10.1182/blood-2022-170288

Published: 2022

Journal Articles

The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Blood (2022) 140 (Supplement 1): 8326–8328.

https://doi.org/10.1182/blood-2022-170790

Published: 2022

Journal Articles

Deep Multi-Omic Analysis of Familial Hemophagocytic Lymphohistiocytosis Reveals Distinctive Immune Features of the Disease

Michael B Jordan, Adi Zoref-Lorenz, Pearce Charles Kieser, Galit Berger, Yehudit Birger, Shai Izraeli, Joanne Yacobovich

Blood (2022) 140 (Supplement 1): 2601–2602.

https://doi.org/10.1182/blood-2022-170799

Published: 2022

Journal Articles

Quercetin ameliorates XIAP deficiency–associated hyperinflammation

Samuel C. C. Chiang, Erika Owsley, Neelam Panchal, Vijaya Chaturvedi, Catherine E. Terrell, Michael B. Jordan, Parinda A. Mehta, Stella M. Davies, Nagako Akeno, Claire Booth, Rebecca A. Marsh

Blood (2022) 140 (7): 706–715.

https://doi.org/10.1182/blood.2021014335

Published: 2022

Includes: Supplemental data

Journal Articles

HLH: birds of a feather flock together

Michael B. Jordan

Blood (2022) 140 (3): 167–168.

https://doi.org/10.1182/blood.2022016712

Published: 2022

Journal Articles

An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis

Blood (2022) 139 (7): 1098–1110.

https://doi.org/10.1182/blood.2021012764

Published: 2022

Includes: Supplemental data

Journal Articles

Safety of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Relationship to Treatment Exposure

Michael B Jordan, Franco Locatelli, Philippe Jacqmin, Christian Laveille, Eric Snoeck, Cristina de Min

Blood (2021) 138 (Supplement 1): 2061.

https://doi.org/10.1182/blood-2021-150256

Published: 2021

Journal Articles

Real-World Treatment Patterns and Outcomes in Patients with Hemophagocytic Lymphohistiocytosis (HLH) and Other Clinical Conditions Treated with Emapalumab: The Real-HLH Study Design

Carl E. Allen, Jennifer Leiding, Shanmuganathan Chandrakasan, Kelly J. Walkovich, Abiola Oladapo, John Yee, Priti Pednekar, Sajjad Raza, Michael B Jordan

Blood (2021) 138 (Supplement 1): 4991.

https://doi.org/10.1182/blood-2021-148555

Published: 2021

Journal Articles

Peri-Transplant Alemtuzumab Levels Predict Risk of Secondary Graft Failure and Inversely Impact CXCL9 Levels after RIC HCT (A Correlative Biology Study to BMT-CTN 1204 RICHI)

Ashley V Geerlinks, Brooks Scull, Christa Krupski, Ryan Fleischmann, Michael A. Pulsipher, Mary Eapen, Jim A. Connelly, Catherine M. Bollard, Sung-Yun Pai, Christine N. Duncan, Leslie S Kean, K. Scott Baker, Lauri S Burroughs, Jeffrey R. Andolina, Michael B Jordan, Tsz-Kwong Man, Carl E. Allen, Rebecca A. Marsh

Blood (2021) 138 (Supplement 1): 748.

https://doi.org/10.1182/blood-2021-145629

Published: 2021

Journal Articles

JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition

Vandana Chaturvedi, Nora Lakes, Minh Tran, Natalie Castillo, Michael B. Jordan

Blood (2021) 138 (12): 1034–1039.

https://doi.org/10.1182/blood.2020007930

Published: 2021

Journal Articles

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis

Vandana Chaturvedi, Rebecca A. Marsh, Adi Zoref-Lorenz, Erika Owsley, Vijaya Chaturvedi, Trung C. Nguyen, Jordana R. Goldman, Michael M. Henry, Jay N. Greenberg, Stephan Ladisch, Michelle L. Hermiston, Michael Jeng, Ahmed Naqvi, Carl E. Allen, Hector R. Wong, Michael B. Jordan

Blood (2021) 137 (17): 2337–2346.

https://doi.org/10.1182/blood.2020009499

Published: 2021

Includes: Supplemental data

Journal Articles

A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies

Adi Zoref-Lorenz, MD, Jun Murakami, MD PhD, Liron Hofstetter, MD, Swaminathan P Iyer, MD, Ahmad S. Alotaibi, MD, Peter Miller, MDPhD, Elad Guber, MD, Shiri Weinstein, MD, Joanne Yacobovich, MD MPH, Sarah Nikiforow, MD PhD, Benjamin L. Ebert, MDPhD, Oren Pasvolsky, MD, Pia Raanani, MD, Arnon Nagler, MD, Nancy Berliner, MD, Naval Daver, MD, Martin H Ellis, Michael B. Jordan, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-143011

Published: 2020

Journal Articles

Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH)

Franco Locatelli, MD PhD, Michael B. Jordan, MD, Carl Allen, Simone Cesaro, MD, Carmelo Rizzari, Anupama Rao, Barbara Degar, MD, Tim Garrington, MD, Julian Sevilla, MD PhD, Maria Caterina Putti, MD, Franca Fagioli, MD, Martina Ahlmann, MD, Jose-Luis Dapena Diaz, Michael Henry, MD, Fabrizio De Benedetti, MD, Alexei Grom, Anna Stoltenberg, Mårten Vågerö, Cristina de Min

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-140692

Published: 2020

Journal Articles

Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-140766

Published: 2020

Journal Articles

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults

Paul La Rosée, AnnaCarin Horne, Melissa Hines, Tatiana von Bahr Greenwood, Rafal Machowicz, Nancy Berliner, Sebastian Birndt, Juana Gil-Herrera, Michael Girschikofsky, Michael B. Jordan, Ashish Kumar, Jan A. M. van Laar, Gunnar Lachmann, Kim E. Nichols, Athimalaipet V. Ramanan, Yini Wang, Zhao Wang, Gritta Janka, Jan-Inge Henter

Blood (2019) 133 (23): 2465–2477.

https://doi.org/10.1182/blood.2018894618

Published: 2019

Journal Articles

Clinical Outcomes and Molecular Responses in Children with Langerhans Cell Histiocytosis Treated with MAPK Pathway Inhibitors

Olive S. Eckstein, MD, Daniel Zinn, MD, Carolyn Fein Levy, MD, Michael M. Henry, MD, Patrick Campbell, MD, Michael B. Jordan, MD, Ashish R Kumar, MD PhD, Carlos Rodriguez-Galindo, MD PhD, Nobuko Hijiya, MD, Oussama Abla, MD, Kenneth L. McClain, MD PhD, Carl E. Allen, MD PhD

Blood (2018) 132 (Supplement 1): 3684.

https://doi.org/10.1182/blood-2018-99-120393

Published: 2018

Journal Articles

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Franco Locatelli, Michael B. Jordan, MD, Carl E. Allen, MDPhD, Simone Cesaro, MD, Carmelo Rizzari, MD, Anupama Rao, MD, Barbara Degar, MD, Timothy Garrington, Julian Sevilla, MD PhD, Maria Caterina Putti, MD, Franca Fagioli, MD, Martina Ahlmann, MD, Jose-Luis Dapena, MD, Alexei A. Grom, MD, Fabrizio De Benedetti, MD, Walter Giovanni Ferlin, PhD, Maria Ballabio, MD, Cristina De Min, MD

Blood (2018) 132 (Supplement 1): LBA-6.

https://doi.org/10.1182/blood-2018-120810

Published: 2018

Journal Articles

Plasma Inflammatory Protein Profiles Distinguish Hemophagocytic Lymphohistiocytosis from Sepsis and SIRS

Harshal Abhyankar, MS, Carl E. Allen, MD PhD, Howard Lin, Baruch Goldberg, Brooks Scull, Kenneth L. McClain, MD PhD, Jordana Goldman, Trung Nguyen, Michael B. Jordan, MD, Tsz-kwong Man, Olive S. Eckstein, MD, Joseph Lubega, Dalia Bashir, Rikhia Chakraborty, PhD BSc, MSc, Hector Wong, Eyal Muscal, Daniel Zinn, MD

Blood (2017) 130 (Supplement 1): 1011.

https://doi.org/10.1182/blood.V130.Suppl_1.1011.1011

Published: 2017

NARROW

Early Response Parameters during Etoposide-Based Hemophagocytic Lymphohistiocytosis Treatment in Children Predict Early Mortality

Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): The into-HLH Registry

The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Deep Multi-Omic Analysis of Familial Hemophagocytic Lymphohistiocytosis Reveals Distinctive Immune Features of the Disease

Quercetin ameliorates XIAP deficiency–associated hyperinflammation

HLH: birds of a feather flock together

An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis

Safety of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Relationship to Treatment Exposure

Real-World Treatment Patterns and Outcomes in Patients with Hemophagocytic Lymphohistiocytosis (HLH) and Other Clinical Conditions Treated with Emapalumab: The Real-HLH Study Design

Peri-Transplant Alemtuzumab Levels Predict Risk of Secondary Graft Failure and Inversely Impact CXCL9 Levels after RIC HCT (A Correlative Biology Study to BMT-CTN 1204 RICHI)

JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis

A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies

Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH)

Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults

Clinical Outcomes and Molecular Responses in Children with Langerhans Cell Histiocytosis Treated with MAPK Pathway Inhibitors

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Plasma Inflammatory Protein Profiles Distinguish Hemophagocytic Lymphohistiocytosis from Sepsis and SIRS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only